Drug major Sun Pharmaceutical Industries on Wednesday said it has entered into a licensing agreement with Ferring Pharmaceuticals to commercialise innovative obstetric drug Caritec in India. One of the company s wholly-owned subsidiaries has entered into a license agreement with Ferring Pharmaceuticals Pvt Ltd a subsidiary of Switzerland-based Ferring Pharmaceuticals to commercialise a room temperature stable formulation of the obstetric drug Caritec in India, Sun Pharma said in a regulatory filing. The drug is indicated for the prevention of excessive bleeding in women after vaginal or caesarean childbirth, it added. As per the agreement, Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name Caritec.
Read more about Drug firm Ipca Laboratories fourth quarter profit up 94% at Rs 161 crore on Business Standard. Shares of Ipca Laboratories were trading at Rs 2,132.30 per scrip on BSE, down 3.06 per cent from the previous close.
Read more about Health ministry panel vetting requests by six cos to make Mucormycosis drug on Business Standard. Development come amid fast spread of disease in various states and shortage of drugs to treat it; Rajasthan has already declared an epidemic
Exclusive content, features, opinions and comment - hand-picked by our editors, just for you.
Pick 5 of your favourite companies. Get a daily email with all the news updates on them.
Track the industry of your choice with a daily newsletter specific to that industry.
Stay on top of your investments. Track stock prices in your portfolio.
NOTE :
The monthly duration product is an auto renewal based product. Once subscribed, subject to your card issuer s permission we will charge your card/ payment instrument each month automatically and renew your subscription.
In the Annual duration product we offer both an auto renewal based product and a non auto renewal based product.
The government is continuously working to reduce regulatory compliance burden on the pharma industry in a bid to improve ease of doing business in the country, Union Minister for Chemicals & Fertilisers D V Sadananda Gowda said on Thursday. Addressing the inaugural session of The India Pharma 2021 & India Medical Device 2021 event here, the minister also emphasised that the domestic pharma industry has the capability to achieve the target of USD 130 billion turnover by 2030. Under the leadership of Prime Minister Narendra Modi, the government continues to strive to improve the ease of doing business in the country. Vigorous effort is on to reduce the regulatory compliance burden on the (pharma) industry, Gowda said.